Prokinetic drugs such as metoclopramide are frequently used as second-line therapy for patients with gastroesophageal reflux disease. However, their beneficial effects remain unclear. Esophageal motor activities and compliance of the esophagogastric junction (EGJ) are important for prevention of gastroesophageal reflux. Although metoclopramide has been reported to increase lower esophageal sphincter (LES) pressure, its effects on EGJ compliance have not been evaluated. In the present study, we investigated the effects of metoclopramide on esophageal motor activities and EGJ compliance.
Introduction
The patients with gastroesophageal reflux disease (GERD) suffer from heartburn and regurgitation, which are caused by reflux of stomach contents, leading to a significant impairment of quality of life. Proton pump inhibitor (PPI) administration is the current mainstay for first-line treatment of GERD because of the consistent inhibitory effect on acid secretion. However, use of a PPI alone is insufficient in approximately 30% of GERD patients. 1 As secondline therapy, prokinetic drugs have been used in clinical settings, though their beneficial effects for GERD are not well elucidated. 2, 3 Metoclopramide, a prokinetic agent, has been widely used for treatment of gastrointestinal motility disorders. In addition to acting as a central dopamine D 2 receptor antagonist, metoclopramide blocks the dopamine D 2 receptor in peripheral nerve endings and promotes release of acetylcholine. As a result, metoclopramide augments gastrointestinal motility and enhances gastric emptying, and also increases lower esophageal sphincter (LES) tone. [4] [5] [6] [7] [8] It has recently been reported that esophageal motor activities and compliance of the esophagogastric junction (EGJ) is important for prevention of gastroesophageal reflux, with the latter considered to cause greater volume reflux of gastric contents into the esophagus. [9] [10] [11] Fundoplication surgery for repairing the EGJ has been consistently shown to prevent pathological gastroesophageal reflux by restoration of normal EGJ compliance.
12,13
An endo-luminal functional lumen imaging probe (EndoFLIP, Crospon Ltd, Galway, Ireland) has been developed as a novel device to determine cross-sectional area (CSA) and distensibility at the EGJ. 9 We previously used this probe and high-resolution manometry (HRM) to show that high-dose mosapride (40 mg), a prokinetic agent that acts on the 5-hydroxytryptamine type 4-receptors, augments peristaltic contractions and mean resting LES pressure, which significantly reduced EGJ compliance, though the effects of mosapride on esophageal motor activity vary at lower doses. 14, 15 Although metoclopramide has been reported to increase LES pressure, its effects on EGJ compliance have not been evaluated. [4] [5] [6] [7] [8] Therefore, the aim of the present study was to investigate the effects of metoclopramide on esophageal motor activities and EGJ compliance in healthy volunteers, for which we employed the EndoFLIP system and high-resolution 36-channel manometry.
Materials and Methods

Subjects and Study Protocol
Nine healthy male volunteers (mean age 25.4 ± 3.1 years) without chest or abdominal symptoms were enrolled in this study. None had a history of cardiac, respiratory, neurologic, or gastrointestinal disorders, or were taking any medications.
Peristaltic esophageal contractions and LES pressure were examined by high-resolution esophageal manometry (ManoScan360; Sierra Scientific Instruments, Los Angeles, CA, USA), while EGJ compliance was investigated using the EndoFLIP system. 9 Prior to each measurement, an intravenous access was obtained. After baseline measurements of esophageal motor activities and EGJ compliance, 10 mg of metoclopramide was administered as an intravenous single bolus. At 15 minutes after administration of metoclopramide, the measurements were repeated. The study protocol was approved by the ethical committee of Shimane University Faculty of Medicine. Written informed consent was obtained from each subject before enrollment in the study, which was carried out in accordance with the Declaration of Helsinki. This study was registered with the University Hospital Medical Information Network clinical trials registry, number UMIN (000013521).
Determination of Esophageal Motor Activity
Esophageal motor activity was determined using highresolution 36-channel manometry, according to a previously reported method. [14] [15] [16] Based on the manufacturer's instructions, the manometric catheter was inserted in a transnasal manner after local anesthesia (2% lidocaine jelly) and measurements were performed in a supine position starting 5 minutes after insertion. Initially, we determined resting LES pressure for at least 5 minutes. Then, esophageal body peristaltic contractions were evaluated after a wet swallow of drinking water (5 mL). That was repeated at intervals of 2 minutes until 5 complete contraction records were obtained. Esophageal body peristaltic contractions were observed in 3 segments (proximal, middle, distal, segments 1, 2, 3, respectively), based on a previous report. 14-16 LES pressure and peak peristaltic contraction pressure in the 3 segments of the esophageal body were analyzed using ManoView analysis software (Sierra Scientific Instruments).
Determination of Esophagogastric Junction Compliance
EGJ compliance was determined by use of the EndoFLIP system. The probe was a 240-cm long catheter with a 3-mm outer diameter and equipped with a 14-cm long bag in the distal end, which is compliant to a maximal diameter of 25 mm. Inside the bag, 16 paired impedance electrodes were placed at 4-mm intervals along with a pressure sensor. As the bag was filled with a specially formulated conductive solution, impedance across each segment was inversely proportional to the CSA of the bag at that locus. This allows the diameter and CSA of the bag to be measured, along with intra-bag pressure. Data from the 16 paired electrodes and pressure sensor were sampled by a recording unit, which displayed them in real time on a monitor. The catheter was calibrated based on the manufacturer's instructions, then inserted in a transnasal manner until the impedance electrodes straddled the EGJ at its mid-point. We ignored peristaltic waves, which were often visible. The bag was inflated to volumes of 20, 30, and 40 mL, with a 30-second recording obtained at each distension volume. We evaluated minimum diameter (Dmin), narrowest CSA, and distensibility index (DI [mm/ mmHg]) at each distension volume, as previously reported. EGJ distensibility index was defined as the narrowest CSA in relation to the corresponding intra-bag pressure and calculated using the following equation: narrowest CSA/intra-bag pressure + intragastric pressure offset.
Statistical Methods
Data are expressed as the mean ± SE. Statistical comparisons between metoclopramide administration and the baseline period were performed used a Wilcoxon signed rank test. Differences at P < 0.05 were considered to be statistically significant. All analyses were performed using SPSS version 19.0 (IBM SPSS Japan Inc, Tokyo, Japan).
Results
All 9 subjects completed the study protocol without any adverse events. EndoFLIP data for 1 were not appropriately recorded due to technical problems, thus those obtained from 8 subjects were analyzed. In addition, data for esophageal motor activity obtained with HRM were successfully recorded in all cases.
Consistent with previous reports, mean resting LES pressure in a supine position was significantly elevated after intravenous ad- ministration of metoclopramide (13.7 ± 9.2 vs 26.7 ± 8.8 mmHg, P < 0.05). In addition, metoclopramide significantly augmented maximal peristaltic contractions, especially in segment 3 (distal; 109.8 ± 45.4 vs 140.5 ± 51.7 mmHg, P < 0.05) ( Fig. 1 and Table 1 ). Contraction pressure in segments 1 and 2 (proximal and middle, respectively) also tended to be elevated after administration, though the differences did not reach statistical significance. On the other hand, metoclopramide did not change EGJ compliance after intravenous administration. When the EndoFILP bag was distended to straddle the EGJ, the bag formed an hourglass shape by central contraction at the diaphragmatic hiatus during both metoclopramide administration and the baseline period (Fig. 2) . There was no statistically significant differences in regard to hiatal minimum diameter (13.8 ± 1.5 vs 13.6 ± 0.7 mm, distention volume 40 mL), CSA (152.4 ± 34.2 vs 146.1 ± 15.3 mm 2 , distention volume 40 mL), or distensibility index (4.5 ± 0.5 vs 4.1 ± 0.5 mm 2 /mmHg, distention volume 40 mL) between the baseline period and following intravenous administration of metoclopramide (Table 2) .
Discussion
GERD is defined as symptoms, such as heartburn and regurgitation, or esophageal mucosal injury produced by gastroesophageal reflux. A disorder of esophageal motor function is one of the important factors for occurrence of GERD. 17 Notably, esophageal , and 40 mL, which gave the bag an hourglass shape from the corresponding intra-bag pressure during both metoclopramide administration and the baseline period. There were no differences in bag shape following metoclopramide administration. (B) Distensibility index (DI) with and without metoclopramide. To determine the DI, intra-bag pressure (x-axis) and hiatal cross-sectional area (CSA; y-axis) were determined with the EndoFLIP bag distended to 20 mL (circles), 30 mL (squares), and 40 mL (triangles). There were no differences between the baseline period and the period following intravenous administration of metoclopramide. 
B
body motor function and LES pressure are considered to be the most relevant factors for preventing gastroesophageal reflux. 18, 19 High LES pressure prevents reflux of gastric contents. In previous studies, low LES pressure and impaired esophageal peristalsis were observed in GERD patients, and free and stress-induced gastroesophageal refluxes are known to frequently occur in those cases. [20] [21] [22] [23] Furthermore, in order to clear gastric contents that have refluxed into the esophagus, efficient esophageal body peristaltic contractions are important. [24] [25] [26] [27] EGJ distensibility, an additional factor that prevents large volume gastroesophageal reflux, has recently drawn interest from researchers. Limited EGJ distensibility reduces large volume fluid reflux from the stomach and that in GERD patients has been reported to be augmented to a greater degree than that seen in healthy controls. [9] [10] [11] Prokinetic agents are expected to improve those antireflux functions and considered to be effective for treatment of GERD. 28 We previously reported that high-dose mosapride (40 mg) not only augmented esophageal peristaltic contractions and mean resting LES pressure, but also reduced EGJ compliance, whereas a standard dosage did not consistently change esophageal motor activity.
14,15
The present is the first study to show the effects of metoclopramide on esophageal motor activity and EGJ compliance in healthy adults using HRM and the EndoFLIP system. Metoclopramide is used as a prokinetic drug and has pharmacological actions similar to mosapride. Consistent with our previous study, metoclopramide was found to augment LES pressure to the same degree as mosapride. However, metoclopramide did not decrease EGJ distensibility, which was different from the effect of mosapride. Collectively, metoclopramide augmented esophageal motor activities, without affecting EGJ distensibility.
Considering our observations, it is important to note that the pharmacological characteristics of mosapride and metoclopramide are different, though both are used for gastrointestinal motility disorders as prokinetic agents. Mosapride mainly stimulates presynaptic 5-HT 4 receptors in the peripheral autonomic motor nervous system and augments acetylcholine release at the neuromuscular junction with augmented gastrointestinal motility. On the other hand, metoclopramide mainly inhibits presynaptic dopamine D 2 receptors and increases acetylcholine release during neuromuscular reactions. These differences between the drugs may result in different effects on EGJ distensibility. In addition, mosapride has few effects on the central nervous system, as it has difficulty crossing the blood brain barrier. 29 There are some limitations to our study. First, we administrated metoclopramide to healthy young volunteers and not GERD patients with impaired esophageal motor functions. In addition, we have intravenously administrated metoclopramide in this study. For evaluating the therapeutic value of metoclopramide for the treatment of GERD, the effect of oral administration need to be studied. Furthermore, the number of subjects enrolled was small and an additional larger study that includes GERD patients may be necessary in the future.
In conclusion, intravenous administration of metoclopramide augmented esophageal body peristalsis and resting LES pressure, without changing EGJ compliance.
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